A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF-Mutant Melanoma at High Risk for Recurrence
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms BRIM8
- Sponsors Roche
- 01 Jan 2020 Results of Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF(v600) mutation-positive melanoma receiving adjuvant vemurafenib has been published in the Annals of Oncology
- 05 Nov 2019 Results assessing the impact of treatment with adjuvant vemurafenib monotherapy on health-related quality of life (HRQOL) in patients with resected stage IIC-IIIC melanoma published in the European Journal of Cancer
- 12 Feb 2018 Results published in the Lancet Oncology